echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > J Clin Oncol: Efficacy and safety of nasoprilumab in the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy

    J Clin Oncol: Efficacy and safety of nasoprilumab in the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy

    • Last Update: 2022-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a serious complication of hematopoietic stem cell transplantation with a high mortality rate and no approved treatment
    .
    HSCT-TMA originates from endothelial cell injury and activates the lectin pathway of complement

    .

    Nasoplimab (OMS721) is a mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor developed for the treatment of HSCT-TMA
    .

    This study is a single-arm, open-label, flight trial to evaluate the safety and efficacy of nasoprilumab in adult patients with HSCT-TMA
    .

    A single-arm, open-label flight trial to evaluate the safety and efficacy of nasoprilumab in adult patients with HSCT-TMA
    .

    Patients were recruited with any of the following three TMAs: atypical hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, or HSCT-TMA
    .
    Nasoprilumab (4 mg/kg) was administered once a week for 4-8 weeks

    .
    The primary endpoint was response rate

    .

    A total of 28 patients were recruited and received at least one dose of nasoprilumab (Master Analysis Set [FAS])
    .
    The overall response rate was 61% , and similar response rates were observed in all patient subgroups defined by baseline characteristics, HSCT characteristics, and HSCT complications
    .

    The overall response rate was 61% The overall response rate was 61%


    100-day survival after diagnosis in the overall population and responders


    100-day survival after diagnosis in the

    overall population and responders 100-day survival after diagnosis in the overall population and responders

    Organ function improvement was achieved in 74% of the overall population
    .
    The 100-day survival rates after diagnosis of HSCT-TMA were 68% and 94% in the overall population and responders, respectively, while the median overall survival in the overall population was 274 days

    .
    In addition, nasoprilumab was well tolerated and no unexpected adverse events occurred

    .

    74% of the total population achieved organ function improvement 74% of the total population achieved organ function improvement


    Overall patient survival


    Overall patient survival rate

    Overall patient survival rate

    In conclusion, in this study, nasoprilumab treatment was safe in HSCT-TMA patients, and could significantly improve the response rate and prolong overall survival
    .

    Nasoprilumab has good safety in patients with HSCT-TMA, and can significantly improve the remission rate and prolong overall survival
    .
    Nasoprilumab has good safety in patients with HSCT-TMA, and can significantly improve the remission rate and prolong overall survival
    .

     

    Original source:

    Original Source: Original Source:

    Samer K.
    Khaled, et al.
    Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy.
    Journal of Clinical Oncology.
    April 20, 2022.
    https: https://ascopubs.
    org/doi/full/10.
    1200/JCO.
    21.
    02389

    Samer K.
    Khaled, et al.
    Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy.
    Journal of Clinical Oncology.
    April 20, 2022.
    https: //ascopubs.
    org/doi/full/10.
    1200/JCO.
    21.
    02389


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.